Euroscreen SA, a Brussels, Belgium-based drug development company, has completed a €10m Series A financing.
The round was led by Vesalius Biocapital II Partners and SRIW (Société Régionale d’Investissement de Wallonie SA).
The company intends to use the capital to develop its main advanced product ESN364 for the treatment of endometriosis.
Led by CEO Jean Combalbert, Euroscreen focuses on the development of novel G Protein Coupled Receptors (GPCR) drug concepts including next generation sex hormone control in woman’s health.
The company, which started its activities as a spin-off of ULB (Université Libre de Bruxelles), is actively seeking collaborations to advance other pharmaceutical candidates, in addition to its ongoing research and licensing partnerships with pharmaceutical companies such as Boehringer-Ingelheim, Cephalon, Grunenthal, HGS, Ortho-McNeil-Janssen Pharmaceuticals, Monogram Biosciences, Novartis and Pfizer.
Euroscreen offers a broad patent portfolio for targets and screening tools to out-license to companies developing therapeutic drugs acting through targets as CCR5, ChemR23, GPR43, GPR7/8, ORL1-R, FPRL2, P2Y4, P2Y11 and P2Y13.